It seems that high dosing is extremely non-toxic in mammals.
Safety Assessment of Astaxanthin - Subchronic Toxicity Study in Rats
Astaxanthin, a naturally occurring xanthophyll, is commercially used as a colouring agent in salmon feed, but also marketed as a dietary supplement. The objective of this study was to investigate the subchronic toxicity of synthetic [3S, 3āS]-Astaxanthin in rats. A powder formulation containing approximately 20% [3S, 3āS]-Astaxanthin was administered via the diet to groups of 10 male and 10 female Wistar rats at concentrations of 5,000, 15,000 and 50,000 ppm for a period of 13 weeks. A formulation of comparable composition but without [3S, 3āS]-Astaxanthin served as a placebo control. There were no effects observed on survival, clinical examinations, clinical pathology, estrous cycle as well as on sperm parameters. At terminal necropsy, a macroscopically visible brown-blue discoloration of the gastrointestinal contents was noted which was considered to be secondary to the violet-brown color of the test material. No other significant or dose-related abnormalities were found in the tissues collected at termination. Our observations support that ingestion of [3S, 3āS]-Astaxanthin of up to 700 - 920 mg/kg bw/day in rats in a gelatin/carboydrate formulation is without adverse effects
Astaxanthin Toxicity Discussionā¦
In our study, the only treatment related effect of the ASTX containing formulation was a brown-blue discoloration of the content in the gastrointestinal tract noted in treated rats after 13 weeks of exposure. This observation was considered to be associated with the intensive coloration of the tested product and was not an adverse toxicological effect. No biologically significant differences in food consumption, body weights, body weight gain, gross findings at necropsy or the histopathological investigation of isolated tissues were associated in a dose related manner with exposure to the test material or the formulation matrix for up to 13 weeks of dosing. Clinical chemistry, hematology, blood clotting times and urinalysis evaluations showed no toxicologically relevant, dose-related effects in group of animals treated with the test article or the formulation matrix relative to the vehicle control group at any study period examined. Results from the functional observational battery conducted during the final week of the study showed no signs of test-substance-related effects in behavior or sensorimotor tests.
The results of this study indicate that ingestion of the [3S, 3ā²S] isomer of astaxanthin of up to 700 and 920 mg ASTX/kg bw/day in a gelatin/carbohydrate formulation is without adverse effect when given orally to rats for 13 weeks of continuous exposure
Full Research paper (PDF) here: Sci-Hub | Safety assessment of [3S, 3ā²S]-astaxanthin ā Subchronic toxicity study in rats | 10.1016/j.fct.2015.04.017
Similarly - no detectable toxicity in mice:
In the repeat-dose toxicity test, 100, 250 and 500 mg/kgĀ·bw astaxanthin showed no abnormalities in terms of body and organ weight as well as hematological and biochemical parameters in clinical observation throughout the pregnancy. During pregnancy, the liver accumulated the highest content of astaxanthin, while the eye exhibited the least. The results indicated that administration of astaxanthin from H. pluvialis throughout pregnancy had no adverse effect on mice.
and a 90 day toxicology study in rats yielded not noticeable toxicity:
Both male and female Sprague-Dawley (SD) rats (12 for each gender) receiving the astaxanthin crystal at 1.2, 240.0, or 750.0 mg/kg/day in olive oil via oral gavage for 90 days showed no changes in body weight gains, hematology and serum chemistry values and hepatic enzyme stability, organ integrity and organ weight. Except the higher food consumption observed in rats receiving 750.0 mg/g astaxanthin crystal, administration of the astaxanthin crystal to 25-27 pregnant female rats in each group throughout the period of organogenesis (G6-G15) produced no adverse effects on fetal organogenesis. Based on the results, we propose that the no-observable-adverse-effect level (NOAEL) of the astaxanthin crystal extracted from genetically modified E. coli K-12 is 750.0 mg/kg bw/day.
Full research Paper (PDF) Here: Sci-Hub | Safety assessment of astaxanthin derived from engineered Escherichia coli K-12 using a 13-week repeated dose oral toxicity study and a prenatal developmental toxicity study in rats | 10.1016/j.yrtph.2017.05.003